NEW YORK (GenomeWeb) — Asuragen and MolecularMD announced today that Canadian regulators have approved their BCR-ABL tests for use in chronic myeloid leukemia (CML) patients.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.